MX2016004088A - Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo. - Google Patents
Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.Info
- Publication number
- MX2016004088A MX2016004088A MX2016004088A MX2016004088A MX2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A
- Authority
- MX
- Mexico
- Prior art keywords
- somatostatin receptor
- agonistic activity
- compound
- medicinal use
- somatostatin
- Prior art date
Links
- 108050001286 Somatostatin Receptor Proteins 0.000 title abstract 3
- 102000011096 Somatostatin receptor Human genes 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000001270 agonistic effect Effects 0.000 title abstract 2
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un agonista del receptor de somatostatina subtipo 2. Un compuesto descrito representado. por la fórmula general (I) en donde todos los símbolos tienen las mismas definiciones como se describió en la descripción; una sal del mismo, un N-óxido del mismo o un solvato del mismo, o un profármaco del anterior es un compuesto de bajo peso molecular que tiene fuerte actividad agonista del receptor de somatostatina subtipo 2, y por lo tanto se puede administrar de una manera simple, tiene una alta estabilidad y tiene baja toxicidad. Por lo tanto, el presente compuesto es útil para la profilaxis y/o terapia de enfermedades relacionadas con somatostatina, tales como acromegalia y obstrucción gastrointestinal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013205027 | 2013-09-30 | ||
| JP2013268902 | 2013-12-26 | ||
| PCT/JP2014/075794 WO2015046482A1 (ja) | 2013-09-30 | 2014-09-29 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004088A true MX2016004088A (es) | 2016-06-06 |
Family
ID=52743606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004088A MX2016004088A (es) | 2013-09-30 | 2014-09-29 | Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9643951B2 (es) |
| EP (1) | EP3053916B1 (es) |
| JP (1) | JP6380402B2 (es) |
| KR (1) | KR20160062023A (es) |
| CN (1) | CN105593221B (es) |
| AU (1) | AU2014325078B2 (es) |
| BR (1) | BR112016007078A2 (es) |
| CA (1) | CA2925651A1 (es) |
| DK (1) | DK3053916T3 (es) |
| ES (1) | ES2716151T3 (es) |
| HU (1) | HUE043374T2 (es) |
| IL (1) | IL244813A0 (es) |
| MX (1) | MX2016004088A (es) |
| PH (1) | PH12016500573A1 (es) |
| PL (1) | PL3053916T3 (es) |
| PT (1) | PT3053916T (es) |
| RU (1) | RU2666352C2 (es) |
| SG (1) | SG11201602477YA (es) |
| TW (1) | TWI628175B (es) |
| WO (1) | WO2015046482A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3484865T3 (da) | 2016-07-14 | 2022-10-31 | Crinetics Pharmaceuticals Inc | Somatostatinmodulatorer og anvendelser deraf |
| MX2019009419A (es) | 2017-02-08 | 2019-10-02 | Ono Pharmaceutical Co | Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo. |
| CA3056131A1 (en) * | 2017-03-16 | 2018-09-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| EA202091559A1 (ru) * | 2018-01-17 | 2020-12-15 | Кринетикс Фармасьютикалс, Инк. | Способ получения модуляторов соматостатина |
| EP3752498B1 (en) * | 2018-02-12 | 2023-06-28 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| TW202016101A (zh) * | 2018-06-15 | 2020-05-01 | 日商小野藥品工業股份有限公司 | 哌啶醇衍生物的新穎鹽及新穎結晶形 |
| ES3022912T3 (en) | 2018-09-18 | 2025-05-29 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| TWI841768B (zh) * | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| PE20231850A1 (es) | 2020-09-09 | 2023-11-21 | Crinetics Pharmaceuticals Inc | Formulaciones de un modulador de somatostatina |
| MX2023009603A (es) | 2021-02-17 | 2023-08-24 | Crinetics Pharmaceuticals Inc | Formas cristalinas de un modulador de somatostatina. |
| CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
| IL320483A (en) * | 2022-10-28 | 2025-06-01 | Basecamp Bio Inc | Somatostatin receptor 2 agonists and uses thereof |
| WO2024129614A1 (en) * | 2022-12-13 | 2024-06-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| AU1285499A (en) | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
| BR9910371A (pt) | 1998-05-11 | 2001-01-09 | Takera Chemical Ind Ltd | Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1227090A4 (en) | 1999-10-07 | 2002-11-20 | Tadeka Chemical Ind Ltd | AMINE DERIVATIVES |
| JP3723071B2 (ja) | 1999-11-10 | 2005-12-07 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| WO2001082925A1 (en) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonists |
| EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| US20050245571A1 (en) | 2001-10-19 | 2005-11-03 | Hidenori Abe | Amine derivative |
| PE20050285A1 (es) * | 2003-06-24 | 2005-06-09 | Novartis Ag | Composicion farmaceutica que comprende analogos ciclicos de somatostatina |
| US20090196912A1 (en) | 2004-07-30 | 2009-08-06 | Gpc Botech Ag | Pyridinylamines |
| CN101258152A (zh) | 2005-07-04 | 2008-09-03 | 阿斯利康(瑞典)有限公司 | 作为pde4抑制剂用于治疗炎症和免疫疾病的吡啶并嘧啶衍生物 |
| TW200726767A (en) | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| US20090258853A1 (en) | 2006-03-13 | 2009-10-15 | Brian Eastman | Somatostatin Agonists |
| CN101506165B (zh) | 2006-08-15 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | 苯基、吡啶和喹啉衍生物 |
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| JP6299591B2 (ja) | 2012-07-03 | 2018-03-28 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
-
2014
- 2014-09-29 BR BR112016007078A patent/BR112016007078A2/pt not_active IP Right Cessation
- 2014-09-29 CA CA2925651A patent/CA2925651A1/en not_active Abandoned
- 2014-09-29 PT PT14847684T patent/PT3053916T/pt unknown
- 2014-09-29 TW TW103133704A patent/TWI628175B/zh not_active IP Right Cessation
- 2014-09-29 DK DK14847684.9T patent/DK3053916T3/en active
- 2014-09-29 WO PCT/JP2014/075794 patent/WO2015046482A1/ja not_active Ceased
- 2014-09-29 MX MX2016004088A patent/MX2016004088A/es unknown
- 2014-09-29 HU HUE14847684A patent/HUE043374T2/hu unknown
- 2014-09-29 JP JP2015539407A patent/JP6380402B2/ja not_active Expired - Fee Related
- 2014-09-29 SG SG11201602477YA patent/SG11201602477YA/en unknown
- 2014-09-29 KR KR1020167008316A patent/KR20160062023A/ko not_active Ceased
- 2014-09-29 RU RU2016111659A patent/RU2666352C2/ru not_active IP Right Cessation
- 2014-09-29 ES ES14847684T patent/ES2716151T3/es active Active
- 2014-09-29 PL PL14847684T patent/PL3053916T3/pl unknown
- 2014-09-29 CN CN201480053967.4A patent/CN105593221B/zh not_active Expired - Fee Related
- 2014-09-29 EP EP14847684.9A patent/EP3053916B1/en not_active Not-in-force
- 2014-09-29 US US15/025,739 patent/US9643951B2/en not_active Expired - Fee Related
- 2014-09-29 AU AU2014325078A patent/AU2014325078B2/en not_active Ceased
-
2016
- 2016-03-29 PH PH12016500573A patent/PH12016500573A1/en unknown
- 2016-03-29 IL IL244813A patent/IL244813A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1223356A1 (en) | 2017-07-28 |
| PT3053916T (pt) | 2019-03-26 |
| JP6380402B2 (ja) | 2018-08-29 |
| AU2014325078A1 (en) | 2016-04-21 |
| AU2014325078B2 (en) | 2018-10-25 |
| TW201602092A (zh) | 2016-01-16 |
| EP3053916A1 (en) | 2016-08-10 |
| ES2716151T3 (es) | 2019-06-10 |
| TWI628175B (zh) | 2018-07-01 |
| WO2015046482A1 (ja) | 2015-04-02 |
| RU2016111659A3 (es) | 2018-03-20 |
| RU2016111659A (ru) | 2017-11-13 |
| KR20160062023A (ko) | 2016-06-01 |
| EP3053916B1 (en) | 2019-01-30 |
| PL3053916T3 (pl) | 2019-06-28 |
| PH12016500573B1 (en) | 2016-07-04 |
| HUE043374T2 (hu) | 2019-08-28 |
| RU2666352C2 (ru) | 2018-09-07 |
| CA2925651A1 (en) | 2015-04-02 |
| US20160311794A1 (en) | 2016-10-27 |
| US9643951B2 (en) | 2017-05-09 |
| DK3053916T3 (en) | 2019-04-15 |
| PH12016500573A1 (en) | 2016-07-04 |
| JPWO2015046482A1 (ja) | 2017-03-09 |
| CN105593221A (zh) | 2016-05-18 |
| IL244813A0 (en) | 2016-05-31 |
| EP3053916A4 (en) | 2017-03-08 |
| SG11201602477YA (en) | 2016-05-30 |
| BR112016007078A2 (pt) | 2017-12-12 |
| CN105593221B (zh) | 2017-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004088A (es) | Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo. | |
| PH12020500485A1 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
| PH12017502363A1 (en) | Brk inhibitory compound | |
| PH12015501996B1 (en) | Heterocyclic compounds and uses thereof | |
| PH12016500170A1 (en) | Formulation of syk inhibitors | |
| JO3452B1 (ar) | بنزاميدات أمينو اريل مغاير كمثبطات كيناز | |
| PH12017501255A1 (en) | Tricyclic spiro compound | |
| PH12015501363B1 (en) | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| MA34064B1 (fr) | Compose heterocyclique | |
| PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| GEP201706725B (en) | Compounds and compositions as inhibitors of mek | |
| JO3442B1 (ar) | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) | |
| PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| MY185061A (en) | Trpv1 antagonists including dihydroxy substituent and uses thereof | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| TR201813294T4 (tr) | N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari. |